X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2627) 2627
Publication (201) 201
Book Review (60) 60
Newsletter (37) 37
Magazine Article (17) 17
Book Chapter (14) 14
Newspaper Article (10) 10
Conference Proceeding (6) 6
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glatiramer acetate (2458) 2458
humans (1748) 1748
multiple sclerosis (1646) 1646
index medicus (1125) 1125
clinical neurology (948) 948
multiple sclerosis - drug therapy (838) 838
female (835) 835
peptides - therapeutic use (748) 748
neurosciences (697) 697
male (665) 665
adult (660) 660
double-blind (583) 583
immunosuppressive agents - therapeutic use (536) 536
animals (501) 501
interferon-beta - therapeutic use (490) 490
multiple sclerosis, relapsing-remitting - drug therapy (452) 452
middle aged (450) 450
neurology (394) 394
placebo-controlled trial (389) 389
experimental autoimmune encephalomyelitis (387) 387
treatment outcome (366) 366
immunology (364) 364
multiple sclerosis - immunology (325) 325
pharmacology & pharmacy (324) 324
interferon-beta (323) 323
interferon beta-1a (315) 315
multiple-sclerosis (308) 308
immunologic factors - therapeutic use (292) 292
disability (289) 289
natalizumab (284) 284
magnetic resonance imaging (277) 277
disease progression (273) 273
multicenter (271) 271
adjuvants, immunologic - therapeutic use (257) 257
drug therapy (253) 253
central-nervous-system (251) 251
interferon beta-1b (251) 251
myelin basic-protein (233) 233
therapy (230) 230
mice (229) 229
care and treatment (225) 225
interferon (220) 220
research (217) 217
interferon beta (216) 216
experimental allergic encephalomyelitis (203) 203
peptides - administration & dosage (194) 194
peptides - pharmacology (194) 194
analysis (192) 192
copolymer 1 (191) 191
medicine & public health (186) 186
peptides - adverse effects (186) 186
multiple sclerosis - therapy (183) 183
t-cells (181) 181
multiple sclerosis - pathology (171) 171
disease (161) 161
health aspects (160) 160
immunosuppressive agents - adverse effects (156) 156
fingolimod (153) 153
immunosuppressive agents - administration & dosage (152) 152
young adult (152) 152
psychiatry (150) 150
multiple sclerosis - physiopathology (149) 149
glatiramer acetate - therapeutic use (146) 146
time factors (146) 146
multiple sclerosis - diagnosis (139) 139
recurrence (139) 139
inflammation (137) 137
adolescent (135) 135
medicine, general & internal (133) 133
disability evaluation (132) 132
relapse rate (132) 132
copaxone (127) 127
immunosuppressive agents - pharmacology (126) 126
immunotherapy (123) 123
neuroprotection (123) 123
t cells (122) 122
remitting multiple-sclerosis (121) 121
brain - pathology (119) 119
clinical trials as topic (119) 119
retrospective studies (118) 118
biological response modifiers (113) 113
disease models, animal (113) 113
progressive multifocal leukoencephalopathy (113) 113
t-lymphocytes - immunology (110) 110
encephalomyelitis, autoimmune, experimental - immunology (109) 109
interferon-beta - administration & dosage (108) 108
mri (107) 107
clinical trials (106) 106
encephalomyelitis, autoimmune, experimental - drug therapy (106) 106
immunomodulation (106) 106
mice, inbred c57bl (106) 106
regulatory t-cells (106) 106
autoimmunity (105) 105
cytokines (105) 105
diagnostic-criteria (103) 103
disease-activity (103) 103
dosage and administration (103) 103
dendritic cells (102) 102
multiple sclerosis, relapsing-remitting - immunology (100) 100
development and progression (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2429) 2429
German (70) 70
Spanish (63) 63
Russian (56) 56
French (20) 20
Hungarian (13) 13
Japanese (13) 13
Czech (10) 10
Polish (6) 6
Portuguese (6) 6
Finnish (5) 5
Chinese (4) 4
Italian (4) 4
Serbian (2) 2
Turkish (2) 2
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, ISSN 1474-4422, 2008, Volume 7, Issue 10, pp. 903 - 914
Journal Article
Journal Article
CNS Drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 401 - 414
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 04/2018, Volume 387, pp. 152 - 156
Glatiramer acetate (GA) 40 mg × 3/weekly was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While the beneficial effect of GA... 
Glatiramer acetate | DTI | Multiple sclerosis | Tract based spatial statistics | MRI | ACCURATE | MECHANISM | ATROPHY | NEUROSCIENCES | BLACK-HOLES | LESIONS | CLINICAL NEUROLOGY | TRIAL | ROBUST | REGISTRATION | BRAIN | Medicine, Experimental | Medical research
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 05/2019, Volume 133, pp. 8 - 14
Complex drugs may be either biological, if the active ingredients are derived from a biological source, or non-biological, if obtained by chemical synthesis.... 
NBCD | Complex drug | Glatiramer | Glatiramoid | MULTICENTER | MULTIPLE-SCLEROSIS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | EQUIVALENCE | Glatiramer acetate | Generic drugs | Independent regulatory commissions | Chemical synthesis
Journal Article